Telehealth clinics, explained: what FDA and the FTC say (not which clinic to use)
Online clinics selling weight-loss and wellness peptides advertise hard. Regulators talk about something narrower: whether the marketing is truthful, whether a product is FDA-approved or compounded, and whether you can tell who actually made it. This page collects what FDA and the FTC have published about those questions. It is not a clinic ranking, and it does not recommend any company.
Facts are as of November 6, 2026. Sources, with retrieval dates, are at the bottom.
What the agencies emphasize
- Compounded drugs sit outside FDA approval; the agency does not pre-check their safety, effectiveness or quality the way it does for approved medicines. [V]
- FDA says telehealth promotion of compounded drugs must be truthful and not misleading, and it has listed claim patterns it treats as false or misleading. [V]
- FDA encourages people buying medicine online — including through telehealth — to research the pharmacy and use its BeSafeRx resources. [V]
- The FTC's health-products guidance expects advertising to be truthful and substantiated with competent, reliable scientific evidence for objective health claims. [V]
What a "telehealth clinic" is, in regulator language
In everyday talk, "telehealth clinic" can mean a video visit, a questionnaire, a mail-order pharmacy, a compounding partner, or a brand that wraps all of those together. FDA's compounding Q&A does not invent a special legal category for that bundle. It talks about online pharmacies and telehealth services that market compounded drugs, and it reminds readers that you may not know which compounder produced what you receive. [V]
That gap — brand on the website, different pharmacy on the label — is one of the themes in FDA's telehealth marketing materials. [V]
What FDA says compounded drugs are (and aren't)
FDA's compounding Q&A is blunt: compounded preparations have not gone through FDA approval, so the agency does not pre-verify safety, effectiveness or quality. [V] Generics are a different path; a generic clears FDA approval, and a compounded preparation does not. [V]
FDA says compounding belongs where an approved medicine cannot meet a patient's clinical need. [V] Unnecessary use, FDA writes, can expose patients to quality problems such as contamination or the wrong amount of active ingredient. [V]
None of that is a ban on compounding. It is FDA's published framing of when compounding is supposed to fit, and what approval does and does not cover.
FDA's reminders for telehealth marketing
On a page aimed at telehealth companies promoting compounded drugs, FDA lists claim patterns it describes as false or misleading, including: [V]
- branding that makes it look as if the telehealth company itself compounded the product
- calling a compounded preparation a "generic," or treating it as identical to an approved medicine
- saying a compounded preparation is FDA-approved or has already been evaluated for safety and effectiveness
- claiming a compounded preparation is clinically proven to match what the approved drug does
- saying a product comes from an "FDA-approved" or "FDA-licensed" pharmacy or outsourcing facility (FDA says it does not approve or license facilities that way)
FDA also points readers to its warning-letter database with the search term "telehealth." [V] Our separate brief on the March 3, 2026 batch of 30 telehealth warning letters covers what that release said about compounded GLP-1 marketing.
“Compounded drugs are not reviewed by the agency for safety, effectiveness or quality prior to marketing”
Buying medicine online: BeSafeRx and identity of the compounder
FDA's compounding Q&A asks whether it is safe to buy compounded drugs online and answers with caution, not a yes/no. It encourages consumers to research an online pharmacy before using it, points to tips for spotting unsafe sites, and recommends the BeSafeRx campaign for safer online pharmacy decisions. [V]
FDA's concern in that Q&A is practical: people buying through telehealth platforms may not know which compounder made the drug, or whether that compounder is appropriately licensed and regulated. [V] BeSafeRx itself is FDA's consumer hub for online pharmacy information, reporting tools and related resources. [V]
Where the FTC fits
The FTC's job on health advertising is different from FDA's drug-approval role. In its Health Products Compliance Guidance, the FTC boils the rules down to two ideas: ads must be truthful and not misleading, and advertisers need adequate substantiation — generally competent and reliable scientific evidence — before making objective health claims. [V]
That guidance also warns that scientific-looking props and fine-print disclaimers do not fix an unsupported main claim, and that ads must not misrepresent whether FDA approved or cleared a product. [V] Our marketing red-flags guide walks through how those ideas show up in peptide pages.
FDA and the FTC share jurisdiction over many health products; FDA generally leads on labeling, the FTC on advertising, and they coordinate under a long-standing liaison arrangement described in the FTC guidance. [V]
Branded self-pay is a different lane
Not every telehealth GLP-1 offer is compounded. On November 5, 2026, LifeMD said its affiliated mail-order pharmacy can dispense Lilly's cash-pay Zepbound and Foundayo after a LifeMD-affiliated provider evaluation. [V] That is the FDA-approved bottle, sold cash-pay — a different story from compounded marketing. Our LifeMD / Lilly self-pay brief stays on what that release said. For company plans that mix approved GLP-1s with peptide compounding language, see our Hims Peptides+ / HHS policy post.
Myths telehealth ads invite
"If it's prescribed online, FDA already reviewed that exact product." A prescription does not turn a compounded preparation into an FDA-approved drug. [V]
"Generic and compounded mean the same thing." FDA separates them: generics are approved; compounded preparations are not. [V]
"The brand on the website is always the pharmacy that made it." FDA has flagged branding that obscures the real compounder. [V]
Peptide Policy Watch
Telehealth clinics, explained: what FDA and the FTC say (not which clinic to use)
Printable checklist
Before you treat a telehealth ad as settled
Points from this story to talk through with a clinician or pharmacist who knows your history.
- Is the product described as FDA-approved, compounded, or something else?
- Does the page name the pharmacy or outsourcing facility that will prepare or dispense it?
- Are health-benefit claims backed by evidence for this product, or only for a different approved medicine?
- If anything is unclear, who can you ask — a licensed clinician, not just a chat bot?
Print view Select it, then use your browser’s Print command to print only this box.
What this page is not
It is not a list of clinics to use or avoid. It does not compare prices, shipping times or customer service. It does not tell anyone what to take, how to take it, or where to order. State pharmacy and medical-board rules sit on top of the federal picture and can differ. For the older case-focused telehealth write-up (FTC privacy case and an earlier FDA letter), start with Telehealth, the FTC and FDA. For how "research use only" labels interact with intended use, see the label decoder.
Sources (retrieved November 6, 2026 unless noted)
- FDA, "Compounding and the FDA: Questions and Answers" [V] — https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA, "FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs" [V] — https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
- FDA, "BeSafeRx: Your Source for Online Pharmacy Information" [V] — https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information
- FTC, "Health Products Compliance Guidance" (notes from prior retrieval Oct. 26 / Nov. 2, 2026; guidance page) [V] — https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
- FDA, "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s," March 3, 2026 [V] — https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
- LifeMD / GlobeNewswire release on Lilly self-pay dispensing, November 5, 2026 (covered in our LifeMD brief) [V] — https://www.globenewswire.com/news-release/2026/11/05/3396309/0/en/lifemd-expands-access-to-lilly-s-self-pay-glp-1-medicines-enabling-option-to-dispense-and-ship-directly-to-patients-nationwide.html
Cite or link to this page
Peptide Policy Watch staff. “Telehealth clinics, explained: what FDA and the FTC say (not which clinic to use).” Peptide Policy Watch. Published November 6, 2026. https://peptidepolicywatch.com/2026/11/06/telehealth-clinics-explained-fda-ftc/
Link: https://peptidepolicywatch.com/2026/11/06/telehealth-clinics-explained-fda-ftc/
Spot a mistake? See how we source and our corrections policy.
Image: AI-generated. Image credits